World Health Organization Issues Warning Over Acute Lack of Weight-Loss Injections

Less than 10% of patients that would benefit from weight-loss injections like Wegovy are able to get them, states the WHO as it publishes its initial guidance on the therapies.

With over a billion individuals worldwide now classified as obese, it is urging more widespread and fairer access to GLP-1 medication.

According to estimates, more than two billion could be living with obesity by 2030 unless action is taken.

"Our new guidance affirms that obesity is a lifelong illness that can be addressed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are major hurdles to universal access to the treatments that can assist patients in reducing substantial weight, says the organization.

Skinny Jab Supply Crisis

Even under the present best projected scenario, the manufacturing of such drugs would only suffice for about 100 million people – fewer than 10% of eligible patients, per the WHO.

The recommendation urges countries and companies to widen access, through approaches like voluntary licensing.

The intellectual property rights on the active ingredient – the primary component of a leading brand – is due to expire in multiple countries in 2026.

The Way Weight-Loss Drugs Work

GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and increase satiety so people consume fewer calories.

People commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.

Studies suggests users may put most of the weight back on within a year of halting the treatment, when their typical hunger return.

To be above a healthy weight raises your risk for developing medical conditions, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.

Obesity concerns people in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.